Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
Finazzi
Guido
G
Ruggeri
Marco
M
Rodeghiero
Francesco
F
Barbui
Tiziano
T
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000139:chemically induced; D015331:Cohort Studies; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology*; D013927:Thrombosis / Q000453:epidemiology* / Q000517:prevention & control
D011799:Quinazolines; C021139:anagrelide; D006918:Hydroxyurea